An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value

Clinical and Translational Oncology

Volumn 10, Issue 4, 2008, Pages 219-226

  Lupu, Ruth ^a   Colomer, Ramón ^b   Menéndez, Javier A ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MD ANDERSON CANCER CENTER   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Breast cancer; Fatty acid synthase; Fatty acids; Metabolism

Indexed keywords

C 75; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; 4 METHYLENE 2 OCTYL 5 OXOFURAN 3 CARBOXYLIC ACID; 4-METHYLENE-2-OCTYL-5-OXOFURAN-3-CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; FASN PROTEIN, HUMAN; GAMMA BUTYROLACTONE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MITOSIS INHIBITION; PROTEIN EXPRESSION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; NEOPLASM; NICK END LABELING; PHYSIOLOGY; RNA INTERFERENCE; THEORETICAL MODEL; TUMOR CELL LINE; WESTERN BLOTTING;

4-BUTYROLACTONE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX, TYPE I; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU NICK-END LABELING; MODELS, THEORETICAL; NEOPLASMS; RNA INTERFERENCE;

EID: 51649108891     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-008-0185-x     Document Type: Article

References (15)

1. Kuhajda FP (2000) Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition 16:202-208
2. Menendez JA, Lupu R (2004) Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: From anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 52:414-426
3. Menendez JA, Lupu R, Colomer R (2005) Targeting fatty acid synthase: potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. Drug News Perspect 18:375-385
4. Kuhajda FP (2006) Fatty acid synthase and cancer: New application of an old pathway. Cancer Res 66:5977-5980
5. Lupu R, Menendez JA (2006) Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology 147:4056-4066
6. Menendez JA, Lupu R (2006) Oncogenic properties of the endogenous fatty acid metabolism: Molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 9:346-357
7. Lupu R, Menendez JA (2006) Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: A new family of anti-cancer agents? Curr Pharm Biotechnol 7:483-493
8. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777
9. Kridel SJ, Lowther WT, Pemble CW 4th (2007) Fatty acid synthase inhibitors: New directions for oncology. Expert Opin Investig Drugs 16:1817-1829
10. Asturias FJ, Chadick JZ, Cheung IK et al (2005) Structure and molecular organization of mammalian fatty acid synthase. Nat Struct Mol Biol 12:225-232
11. Maier T, Jenni S, Ban N (2006) Architecture of mammalian fatty acid synthase at 4.5 A resolution. Science 311:1258-1262
12. Asturias FJ (2006) Mammalian fatty acid synthase: X-ray structure of a molecular assembly line. ACS Chem Biol 1:135-138
13. Menendez JA, Mehmi I, Atlas E et al (2004) Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 24:591-608
14. Menendez JA, Ropero S, Mehmi I et al (2004) Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: A novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Oncol 24:1369-1383
15. Menendez JA, Oza BP, Colomer R, Lupu R (2005) The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol 26:1507-1515